Patterns and Prevalence of FDG Extravasation in PET/CT Scans
NCT03041090 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 133
Last updated 2019-06-14
Summary
PET (Positron Emission Tomography) images are used to help make patient management decisions in staging and treatment assessment, often after a cancer diagnosis.
Improper injections of PET tracers (dye) may occur approximately 15% of the time. This is known as extravasation or infiltration, and it compromises the doctor's ability to read the PET image. Often, the site where the tracer is injected into the vein (usually in the inside of the elbow) are not in the images taken, so reading physicians are unaware that an extravasation or infiltration has occurred.
Technology exists to capture time activity curves (amount of tracer in a location over a period of time) during the PET tracer uptake period (usually once the tracer is injected, the tracer circulates for 60 minutes prior to images), which can enable physicians to accurately detect extravasations and infiltration. This information is currently unavailable to physicians reading routine PET/CT (computed tomography) scans.
Time activity curves information gathered from these sensors during the circulation period appear to match the brief pictures taken approximately 70 minutes after the tracer injection.
This study will determine if these time activity curves correspond to PET images of the injection site taken during the tracer uptake period. If time activity curves correspond to PET images, they can be used to determine if the tracer was properly injected. If there was an improper injection, clinicians can be alerted to this fact and interpret the image with this additional information.
Conditions
- Intravenous Infiltration
Interventions
- DEVICE
-
Lucerno ID (identification) System
The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
Sponsors & Collaborators
-
Lucerno Dynamics Limited Liability Company (LLC)
collaborator UNKNOWN -
St. Louis University
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-03-31
- Primary Completion
- 2017-12-31
- Completion
- 2017-12-31
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
FDG-PET Imaging in Complicated Diabetic Foot
NCT00194298 ·Status: ACTIVE_NOT_RECRUITING
-
Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers
NCT01421953 ·Status: COMPLETED ·Phase: NA
-
A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
NCT05160480 ·Status: ENROLLING_BY_INVITATION
-
Tumor Hypoxia With HX4 PET in Several Diseases
NCT02584400 ·Status: TERMINATED ·Phase: PHASE2
-
Radionecrosis and FDG PET
NCT02391246 ·Status: UNKNOWN
-
Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT
NCT03519659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
NCT01434797 ·Status: COMPLETED
-
A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans
NCT01542541 ·Status: COMPLETED ·Phase: NA
-
PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)
NCT00201942 ·Status: COMPLETED ·Phase: PHASE3
-
Role of FDG PET/CT in Patients With Metastasis of Unknown Origin
NCT06055764 ·Status: NOT_YET_RECRUITING
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT
NCT04622631 ·Status: UNKNOWN
-
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
NCT02378337 ·Status: COMPLETED
-
Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer
NCT01190527 ·Status: COMPLETED ·Phase: NA
-
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
NCT01931709 ·Status: TERMINATED ·Phase: NA
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
NCT06122610 ·Status: RECRUITING ·Phase: PHASE1
-
EXPLORER PET/CT in Healthy Volunteers
NCT04110743 ·Status: COMPLETED ·Phase: NA
-
A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)
NCT01697930 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis
NCT04762719 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Infiltration Effect on SUV
NCT03320564 ·Status: TERMINATED ·Phase: NA
-
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
NCT01383135 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer
NCT03100136 ·Status: COMPLETED ·Phase: PHASE1
-
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
NCT04258592 ·Status: TERMINATED ·Phase: PHASE1
-
Single-tracer Multiparametric PET Imaging
NCT06014515 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Imaging Study for FdCyd and THU Cancer Treatment
NCT01479348 ·Status: TERMINATED ·Phase: EARLY_PHASE1